Stockscreener 앱 받기
2.01
3.37%
-0.07
시간 외 거래:
2.01
전일 마감가:
$2.08
열려 있는:
$2.04
하루 거래량:
67,720
Relative Volume:
0.52
시가총액:
$149.42M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.6422
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
+13.56%
1개월 성능:
-10.67%
6개월 성능:
-31.16%
1년 성능:
+11.05%
1일 변동 폭
$1.95
$2.16
1주일 범위
$1.70
$2.16
52주 변동 폭
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
678-392-3419
주소
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
IKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
2.01 | 131.58M | 0 | -19.57M | -17.24M | -3.13 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st
Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks
13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development - Stock Titan
Barclays PLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) - PR Newswire
Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH - Seeking Alpha
Geode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
IKTInhibikase Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
In wake of Anthos buyout, CFO McIntyre joins Inhibikase - biocentury.com
Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks
Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com
Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN
Inhibikase Therapeutics appoints new CFO - Investing.com Australia
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewswire
Strategic Hire: Venture Capital Veteran and Life Sciences CFO Expert Takes Helm at Inhibikase - Stock Titan
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India
HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World
Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan
INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria
Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire
Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks
Inhibikase enhances leadership with new appointments - Investing.com
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
What is HC Wainwright’s Estimate for IKT Q1 Earnings? - Defense World
HC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT) - MSN
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):